by Raynovich Rod | Jan 16, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Momentum is Easing in Biotech -Is the JPMorgan rally Over? We need to see which stocks hold up when momentum decelerates. it has been a good run for the week but not too frothy.We are “content challenged” in that we sat through three days of interesting...
by Raynovich Rod | Jan 14, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPM Notes #2 : Investors buy into Life science innovation After a lackluster day Monday the tape for JPM life science sector stocks picked up with a decent rally. Major ETFs reversed the trend from yesterday with the IBB up 1.64% and the XBI up 2.94% despite NASDAQ...
by Raynovich Rod | Jan 13, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 1/14/2 12:30 EDT…Very Bullish Tape today–Update at Close IBB up 1.27% , XBI up 2.47%. Gene therapy stocks are on a tear even before BLUE and EDIT (both up >5%) present later today and tomorrow. ===== J.P.Morgan Healthcare Conference Notes #1:...
by Raynovich Rod | Jan 6, 2020 | Biopharmaceuticals, Macro
Update-1 1/9/20 “Sigh of Relief” rally for second day -Don’t Fight the FED Dont confuse a momentum rally with fundamental analysis as we are at new highs with market PEs>18. Large cap biiopharmas are at new highs Mid-cap 2%+ winners today: ACAD,...
by Raynovich Rod | Dec 22, 2019 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-4 January 2 , 2020. 12:11 EST….. Biotechs and Healthcare lagging a bit in the New Year. Watch rotation into other sectors -tech, financial, energy; update at end of week. Many mid and small caps are weak despite NAZ up 0.66%. Russell 2000 is down 0.79%....
by Raynovich Rod | Dec 17, 2019 | Biopharmaceuticals
update 12/21…Looks like all problems have been cleared and content visible. ====== You may have experienced site problems yesterday related to hosting but all content should be available today; update later today.
by Raynovich Rod | Dec 9, 2019 | Biopharmaceuticals, Macro
Update-1 …12/12/19…China Deal Announcement Boosts Dow S&P and NASDAQ. IBB up 0.68%, XBI up 0.58%, XLV up 0.93%. Large cap leaders: ABBV ALXN BMY, Chips, energy, financials strong; real estate weak. 10 year yield moves up to 1.894% =========== Early...
by Raynovich Rod | Nov 30, 2019 | Biopharmaceuticals
Update-2 …12/3…Biotech among the leading sectors on a sell-off day With NASDAQ off 0.55% and the S&P down 0.68%, biotech stocks were oblivious to the trade worries and had a huge rally driven by gene therapy stocks. The XBI was up 1.47% and most mid...
by Raynovich Rod | Nov 24, 2019 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/25/19… Rally right on track driven by NVS/MDCO deal, new product surge and cheap money from FED. As we said many time on this site XBI is the bellwether up 4.25% today (UP 13% in one month) as biotech stocks broke out last week. IBB up 2.46%. We...
by Raynovich Rod | Nov 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/20…China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on...
